• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
KaloBios Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 Product Image

KaloBios Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446160
  • November 2010
  • 43 pages
  • GlobalData

KaloBios Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “KaloBios Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- KaloBios Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of KaloBios Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
KaloBios Pharmaceuticals, Inc. Snapshot
KaloBios Pharmaceuticals, Inc. Overview
Key Information
Key Facts
KaloBios Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
KaloBios Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
KaloBios Pharmaceuticals, Inc. – Pipeline Products Glance
KaloBios Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
KaloBios Pharmaceuticals, Inc. – Drug Profiles
KB001
Product Description
Mechanism of Action
R&D Progress
KB002/003
Product Description
Mechanism of Action
R&D Progress
KB003
Product Description
Mechanism of Action
R&D Progress
KB004
Product Description
Mechanism of Action
R&D Progress
KaloBios Pharmaceuticals, Inc. – Pipeline Analysis
KaloBios Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
KaloBios Pharmaceuticals, Inc. Pipeline Products By Target
KaloBios Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
KaloBios Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
KaloBios Pharmaceuticals, Inc. – Recent Pipeline Updates
KaloBios Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
May 17, 2010: KaloBios Presents Data From Initial Clinical Studies With KB001
May 17, 2010: KaloBios Presents Data From Initial Clinical Studies With KB001
Oct 15, 2009: KaloBios Declares Phase I/II Trial Results Of KB001 Antibody For Fighting Pseudomonas Infection In Cystic Fibrosis Patients
Oct 15, 2009: KaloBios Declares Phase I/II Trial Results Of KB001 Antibody For Fighting Pseudomonas Infection In Cystic Fibrosis Patients
May 19, 2008: KaloBios Initiates Phase I/II Trial Of Humaneered Monoclonal Antibody KB001 For Treatment Of Pseudomonas Infections In Mechanically Ventilated Patients
Apr 28, 2008: KaloBios Completes Patient Dosing In Its U.S. Phase 1 Trial Of Its Third Drug Candidate, KB003
Apr 28, 2008: KaloBios Completes Patient Dosing In Its U.S. Phase 1 Trial Of Its Third Drug Candidate, KB003
Apr 28, 2008: KaloBios Completes Patient Dosing In Its U.S. Phase 1 Trial Of Its Third Drug Candidate, KB003
Apr 28, 2008: KaloBios Completes Patient Dosing In Its U.S. Phase 1 Trial Of Its Third Drug Candidate, KB003
Apr 28, 2008: KaloBios Completes Patient Dosing In Its U.S. Phase 1 Trial Of Its Third Drug Candidate, KB003
Financial Deals Landscape
KaloBios Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
KaloBios Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
KaloBios Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
KaloBios Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
KaloBios Pharmaceuticals Secures $32 Million In Series D Financing
KaloBios Pharmaceuticals Secures $20 Million In Series C Financing
KaloBios Pharmaceuticals Secures $20 Million In Series B Financing
Sanofi Pasteur Enters Into Co-Development Agreement With KaloBios
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS